Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) FCF Margin (2024 - 2025)

Kairos Pharma's FCF Margin history spans 2 years, with the latest figure at 1.61% for Q2 2025.

  • For Q2 2025, FCF Margin fell 140161.0% year-over-year to 1.61%; the TTM value through Dec 2025 reached 2.21%, up 579.0%, while the annual FY2025 figure was 6.88%, 293.0% down from the prior year.
  • FCF Margin reached 1.61% in Q2 2025 per KAPA's latest filing, down from 1.43% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1400.0% in Q2 2024 to a low of 225.0% in Q1 2024.